Patent · US Active

Hybridoma cell line 10G4 and a monoclonal antibody against the total of aflatoxin B1, B2, G1 and G2

US8841419B2 · kind B2 · utility

0Cited by
0References
3Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 17, 2013
Grant dateSep 23, 2014
Priority date
Expiry dateJan 17, 2033

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N33/577
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

Hybridoma cell line 10G4 and monoclonal antibody against total aflatoxins produced by the hybridoma cell line 10G4. The hybridoma cell line 10G4 is used to produce the monoclonal antibody that binds specifically total aflatoxin B1, B2, G1 and G2. The titer of the mouse ascites antibody produced by the 10G4 treated mouse is determined through non-competitive enzyme-linked immunosorbent assay and the titer can reach up to 5.12×105. The monoclonal antibody against total aflatoxin B1, B2, G1 and G2 are used for better identification of aflatoxin B1, B2, G1 and G2 with good consistency. The 50% inhibitory concentrations (IC50) of the antibody against aflatoxin B1, B2, G1 and G2 are 2.09 ng/mL, 2.23 ng/mL, 2.19 ng/mL and 3.21 ng/mL respectively. The range of cross reaction rate for aflatoxin B1, B2, G1 and G2 is about 65.2%-100%. The antibody is used for quantitative measurement of total aflatoxin B1, B2, G1 and G2.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.